Barclays Maintains Overweight on Regenxbio, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Regenxbio (NASDAQ:RGNX) and raises the price target from $45 to $55.
March 07, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Regenxbio and raises the price target from $45 to $55.
The upgrade in price target by Barclays, a major financial institution, indicates a strong positive outlook on Regenxbio's stock. This is likely to influence investor sentiment positively in the short term, potentially leading to an increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100